Corporate Profile

Virionics is a privately-held biotechnology company that was founded to develop, manufacture and commercialize affordable therapies and vaccines to treat diseases affecting mankind.

Virionics is the parent company of C-VIRION CORPORATION (C-VIRION) and AbGenesis, Inc., and serves as a vehicle for new product development opportunities.

C-VIRION focuses on the clinical and regulatory development and the commercialization of drug and protein products for the treatment and prevention of hepatitis C viral disease (HCV) while AbGenesis utilizes immuno-therapies to fight disease through antibody-based therapeutics.

C-VIRION is preparing to enter clincial trials with its lead product, C-Vax, in a Phase I/II clinical study in late 2009. C-Vax is being developed for the prevention and treatment of hepatitis C infection. Several other producst are in the pipeline for treatment of chronic hepatitis C infection.

AbGenesis, is conducting preclinical research with drug candidates in the therapeutic areas of Alzheimer's Disease, cancer, chronic pain, asthma, hormone ablation, drug addiction, obesity, and other major disease categories. This business acquired a platform technology for making drugs useful in a variety of therapeutic areas.

Virionics licensed and maintains an extensive portfolio of U.S. and international patents from the National Institutes of Health (NIH). Years of discovery, basic research and optimization have been completed by the inventors with several millions of dollars of funding from research grants invested in each program. The Company has completed the licensing of these patented technologies and is now preparing them for clinical and regulatory development and corporate partnering relationships.

Virionic's clinical development staff and experienced project managers will orchestrate all of the activities of highly qualified clinical research organizations (CROs), contract GMP manufacturing organizations(CMOs) and other third party consultants to guide our products through Phase I and Phase II clinical trials. Experienced business development staff will utilize their contacts to attract corporate partners to fund product-specific programs in exchange for marketing rights in certain market regions. The costly pivotal Phase III registration studies will generally be conducted in collaboration with one or more corporate partners and out-licensed on a product-by-product basis.